First Human Infection of Shamonda Virus Reported in France
French health authorities confirm the inaugural human case of the Shamonda virus, previously only found in animals, amid rising infection concerns.
Kenya confirms nine cases of Bundibugyo virus disease following an imported case.
A study reveals 18.3% of blood donors in Ghana tested positive for reactive infection markers.
IDWeek 2026 highlights advancements in long-acting HIV antibodies and antifungal treatments.
In a significant development, French health officials have reported the first known human infection of the Shamonda virus, a pathogen previously identified only in animals. The patient, who was severely immunocompromised, succumbed to the virus in early October while receiving treatment in Lyon. The exact circumstances surrounding the transmission remain unclear, with investigations ongoing to determine the virus's role in the patient's death.
This week also saw Kenya grappling with the Bundibugyo virus, which has led to nine confirmed cases, including eight relatives and healthcare workers linked to an imported case. The initial patient, a 40-year-old man from the Democratic Republic of Congo, tested positive shortly after arriving in Nairobi on October 3 and died within 58 hours. Health authorities have initiated extensive contact tracing, identifying 135 potential contacts, and are reviewing execution protocols to enhance response measures.
At IDWeek 2026, researchers presented findings from a retrospective study on blood donors in Ghana, revealing that 18.3% of 5,210 records contained at least one reactive infection marker. The most common markers included treponemal infections, hepatitis C, hepatitis B, and HIV. These findings underscore the need for improved screening and confirmatory testing to ensure better healthcare linkage for affected individuals.
The conference also highlighted advancements in HIV treatment, with TaiMed Biologics discussing investigational long-acting antibodies. Early studies indicated that these antibodies could be administered every 8 to 12 weeks with minimal adverse effects. A phase 2b trial is currently underway to assess their efficacy in a larger cohort of adults, marking a potential breakthrough in HIV management.
As health authorities continue to respond to these emerging threats, the implications for public health are significant. The rise in infections, particularly in vulnerable populations, emphasizes the need for robust surveillance and preparedness strategies. Upcoming research and findings from IDWeek will likely inform future policies and practices in infection control and prevention.
